Autolus Therapeutics Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Autolus Therapeutics stock.
View analyst ratings for Autolus Therapeutics or view top-rated stocks.

Wall Street analysts have given Autolus Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Autolus Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Autolus Therapeutics saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 1,710,000 shares, an increase of 130.0% from the January 28th total of 743,600 shares. Based on an average trading volume of 578,800 shares, the short-interest ratio is presently 3.0 days.
View Autolus Therapeutics' Short Interest.

Autolus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for Autolus Therapeutics.

Autolus Therapeutics will be holding an earnings conference call on Thursday, March 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Autolus Therapeutics plc (NASDAQ:AUTL) announced its earnings results on Tuesday, November, 10th. The company reported ($0.72) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by $0.01. The company had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.31 million. Autolus Therapeutics had a negative net margin of 8,652.90% and a negative trailing twelve-month return on equity of 54.01%.
View Autolus Therapeutics' earnings history.

Autolus Therapeutics' stock was trading at $6.77 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AUTL stock has increased by 1.3% and is now trading at $6.86.
View which stocks have been most impacted by COVID-19.

8 brokers have issued 12 month target prices for Autolus Therapeutics' shares. Their forecasts range from $9.00 to $38.00. On average, they expect Autolus Therapeutics' share price to reach $21.71 in the next year. This suggests a possible upside of 216.5% from the stock's current price.
View analysts' price targets for Autolus Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Autolus Therapeutics include Alector (ALEC), Atara Biotherapeutics (ATRA), Vaxcyte (PCVX), Adverum Biotechnologies (ADVM), Coherus BioSciences (CHRS), Mesoblast (MESO), Aligos Therapeutics (ALGS), Inhibrx (INBX), Cortexyme (CRTX), Taysha Gene Therapies (TSHA), Black Diamond Therapeutics (BDTX), Cellectis (CLLS), TCR2 Therapeutics (TCRR), Aerie Pharmaceuticals (AERI) and Passage Bio (PASG).
View all of AUTL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Autolus Therapeutics investors own include Sorrento Therapeutics (SRNE), CRISPR Therapeutics (CRSP), VBI Vaccines (VBIV), GW Pharmaceuticals (GWPH), ImmunoGen (IMGN), Teva Pharmaceutical Industries (TEVA), TG Therapeutics (TGTX), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP) and Advanced Micro Devices (AMD).

(AUTL) raised $125 million in an IPO on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."

Autolus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Schroder Investment Management Group (3.20%), Baker BROS. Advisors LP (1.50%), BlackRock Inc. (0.57%), JPMorgan Chase & Co. (0.49%), Renaissance Technologies LLC (0.15%) and Victory Capital Management Inc. (0.15%).

AUTL stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., and Victory Capital Management Inc..

AUTL stock was bought by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, Schroder Investment Management Group, JPMorgan Chase & Co., Pendal Group Limited, Renaissance Technologies LLC, and Wells Fargo & Company MN.

Shares of AUTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AUTL stock can currently be purchased for approximately $6.86.

Autolus Therapeutics has a market capitalization of $358.44 million and generates $2.91 million in revenue each year. The company earns $-123,850,000.00 in net income (profit) each year or ($2.88) on an earnings per share basis.

Autolus Therapeutics employs 290 workers across the globe.

The official website for Autolus Therapeutics is www.autolus.com.

Autolus Therapeutics is headquartered at FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ.

Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company can be reached via phone at 44-20-3829-6230 or via email at [email protected]